(Total Views: 692)
Posted On: 08/09/2021 7:53:21 PM
Post# of 145874
Trodelvy was the last mTNBC drug to be approved. It received accelerated approval and marketing based on phase 2 trial data and then received full approval on the interim data from it's phase 3 trial. On the metrics we do know leronlimab beats Trodelvy and doesn't have the nasty side effects.
Cytodyn is unlikely to receive accelerated approval based on phase 2 data because of the trial size. However after approval of any other indication in 2022 Cytodyn will have the funds to expand the patient population in phase 3 and is likely to get accelerated approval and marketing at interim on phase 3 and full approval at the end of the trial.
Cytodyn is unlikely to receive accelerated approval based on phase 2 data because of the trial size. However after approval of any other indication in 2022 Cytodyn will have the funds to expand the patient population in phase 3 and is likely to get accelerated approval and marketing at interim on phase 3 and full approval at the end of the trial.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)